4 tappan terrace LLC

4 tappan terrace
ardsley, new york 10502

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 08, 2014

NYS DOS ID#
4558661

County
WESTCHESTER

Jurisdiction
ARIZONA

Registered Agent
NONE

NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY

Name History
2014 - 4 TAPPAN TERRACE LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • 21st-Century Span: Bridge of Grand Ambitions Is Set to Open at the Tappan Zee
    By JOSEPH BERGER - Thursday Aug 24, 2017

    At a cost of $4 billion, the new structure, is scheduled to see its first drivers early Saturday, and will eventually be able to carry 140,000 cars a day.

    Source: NYT > Home Page
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York
  • Remains of Tappan Zee Bridge to be scattered across New York
    By Albany Bureau Chief - By Albany Bureau Chief - Tuesday Jul 18, 2017

    Eight N.Y. counties have asked for pieces of the old bridge, which is being replaced by a $4 billion bridge named for former Gov. Mario Cuomo. 

    Source: USA Today
  • Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study
    By Ben Fidler - Wednesday Nov 15, 2017

    Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acorda (NASDAQ: ACOR) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases […]

    Source: Xconomy New York